Valuation: Perspective Therapeutics, Inc.

Market Cap 248M 220M 204M 186M 350M 23.51B 356M 2.45B 962M 12.27B 930M 910M 39.11B P/E 2026 *
-2.18x
P/E 2027 * -2.04x
Enterprise Value 81.16M 72.14M 66.86M 60.84M 115M 7.7B 117M 804M 315M 4.02B 305M 298M 12.81B EV / Sales 2026 *
273x
EV / Sales 2027 * 56.9x
Free-Float
91.77%
Yield 2026 *
-
Yield 2027 * -
1 day-7.26%
1 week-18.42%
Current month-21.09%
1 month-24.65%
3 months-27.42%
6 months-48.33%
Current year-21.09%
1 week 2.15
Extreme 2.15
2.52
1 month 2.15
Extreme 2.15
3.03
Current year 2.15
Extreme 2.15
6.16
1 year 1.96
Extreme 1.955
6.16
3 years 1.6
Extreme 1.6
19.05
5 years 1.6
Extreme 1.6
19.05
10 years 1.6
Extreme 1.6
28.1
Manager TitleAgeSince
Chief Executive Officer 54 05/02/2023
Director of Finance/CFO 59 04/09/2025
Chief Tech/Sci/R&D Officer - 08/07/2026
Director TitleAgeSince
Director/Board Member 54 05/02/2023
Chairman 63 03/02/2023
Director/Board Member 60 05/02/2023
Date Insider Type Main position Quantity % Market Cap. Importance
4/9/26 SellCompany -167,149 0.1464%
2/9/26 SellCompany -42,129 0.0369%
1/9/26 SellCompany -35,769 0.0313%
Change 5-day change 1-year change 3-year change Capi.($)
-7.26%-18.42%-51.67%-27.57% 248M
-6.60%-8.56%+49.38%+64.90% 65B
+0.78%+6.13%+10.16%+78.13% 51.2B
-0.08%-0.85%-0.41%+61.27% 51.19B
-1.53%+2.70%+30.48%+41.25% 43.93B
-1.34%+4.12%+16.64%+120.28% 41.96B
-5.97%-6.22%+228.95%+483.48% 38.14B
+2.16%+10.36%+18.92%+59.70% 33.24B
-0.90%-10.49%+37.09%+1.80% 25.2B
-0.72%+0.04%+25.25%+25.28% 22.5B
Average -2.14%-1.88%+36.48%+90.85% 37.26B
Weighted average by Cap. -1.91%-0.27%+44.54%+105.33%

Financials

2026 *2027 *
Net sales 297K 264K 245K 223K 421K 28.22M 427K 2.94M 1.15M 14.73M 1.12M 1.09M 46.94M 296K 263K 244K 222K 419K 28.12M 426K 2.93M 1.15M 14.67M 1.11M 1.09M 46.77M
Net income -114M -101M -94.01M -85.53M -161M -10.83B -164M -1.13B -443M -5.65B -428M -419M -18.01B -136M -121M -112M -102M -193M -12.95B -196M -1.35B -530M -6.76B -512M -501M -21.54B
Net Debt -167M -148M -137M -125M -236M -15.81B -239M -1.65B -647M -8.25B -625M -612M -26.3B -231M -205M -190M -173M -327M -21.91B -332M -2.29B -896M -11.43B -866M -848M -36.45B
Projected Income Statement - Annual - Perspective Therapeutics, Inc.
Logo Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. It is also developing imaging diagnostics that incorporate the same targeting moieties, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. It has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.
Employees
165
Date Price Change Volume
16/10/26 US$2.170 -7.26% 1,669,659
15/10/26 US$2.340 +4.46% 1,189,876
14/10/26 US$2.240 -1.32% 1,394,498
13/10/26 US$2.270 -9.92% 1,309,910
12/10/26 US$2.520 -5.26% 640,582
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Perspective Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
2.170USD
Average target price
12.29USD
Spread / Average Target
+466.16%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Perspective Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. CATX Stock